Abstract
Malpractices of pharmaceutical companies in marketing their products are
widely becoming common. These practices not only involve the pharmaceutical
companies but are also associated with other professions. These may include nurses,
doctors, technicians, pharmacists, and cosmetic sellers, among others. Traders of
pharmaceutical companies give these professionals handsome incentives and subtly ask
them to market their products without letting them know about the actual performance
of the product whether it is a drug, cosmetic product, food, etc. Such products can have
many damaging side effects ranging from minor to major. They can even sell their
low-cost products by doubling the actual retail price just to have some extra money.
Such practices compromise the doctoral-patient relationship of trust and mutual
understanding and thus raise questions on the sanctity of the healthcare system. This
piece of literature has been created to discuss issues related to the unethical behavior of
pharmaceutical companies. The data shed light on the required steps for mainstreaming
ethical practices. It is required to implement proper ethical guidelines within each
sector of healthcare, primarily the pharmaceutical domain.